AIMS: To measure vascular endothelial growth factor (VEGF-A) mRNA in a large, diverse cohort of tumours and to investigate whether VEGF-A expression is associated with markers of hypoxia, including hypoxia inducible factor 1alpha (HIF-1alpha) and carbonic anhydrase IX (CA9). METHODS: The expression of VEGF-A and CA9 was assessed in 5067 fresh frozen human tissue samples and 238 cell lines by DNA microarray analysis. In addition, tissue microarrays were constructed from 388 malignancies to investigate the expression of VEGF-A and HIF-1alpha by in situ hybridisation and immunohistochemistry, respectively. RESULTS: VEGF-A was significantly upregulated in primary malignancies of the breast, cervix, colon and rectum, oesophagus, head and neck, kidney, ovary, skin, urinary system, and white blood cells by DNA microarray analysis. However, VEGF-A expression only correlated with CA9 expression in renal tissues. In the tissue microarrays, HIF-1alpha positive cores showed a significant increase in VEGF-A expression in lung, ovary, soft tissue, and thyroid malignancies. CONCLUSIONS: The expression of VEGF-A is upregulated in a large proportion of human malignancies, and may be associated with markers of hypoxia. VEGF-A expression can be induced in the absence of hypoxia and hypoxia does not always provoke VEGF-A upregulation in tumours.
AIMS: To measure vascular endothelial growth factor (VEGF-A) mRNA in a large, diverse cohort of tumours and to investigate whether VEGF-A expression is associated with markers of hypoxia, including hypoxia inducible factor 1alpha (HIF-1alpha) and carbonic anhydrase IX (CA9). METHODS: The expression of VEGF-A and CA9 was assessed in 5067 fresh frozen human tissue samples and 238 cell lines by DNA microarray analysis. In addition, tissue microarrays were constructed from 388 malignancies to investigate the expression of VEGF-A and HIF-1alpha by in situ hybridisation and immunohistochemistry, respectively. RESULTS:VEGF-A was significantly upregulated in primary malignancies of the breast, cervix, colon and rectum, oesophagus, head and neck, kidney, ovary, skin, urinary system, and white blood cells by DNA microarray analysis. However, VEGF-A expression only correlated with CA9 expression in renal tissues. In the tissue microarrays, HIF-1alpha positive cores showed a significant increase in VEGF-A expression in lung, ovary, soft tissue, and thyroid malignancies. CONCLUSIONS: The expression of VEGF-A is upregulated in a large proportion of humanmalignancies, and may be associated with markers of hypoxia. VEGF-A expression can be induced in the absence of hypoxia and hypoxia does not always provoke VEGF-A upregulation in tumours.
Authors: Vickie Hanrahan; Margaret J Currie; Sarah P Gunningham; Helen R Morrin; Prudence A E Scott; Bridget A Robinson; Stephen B Fox Journal: J Pathol Date: 2003-06 Impact factor: 7.996
Authors: C Pupilli; L Lasagni; P Romagnani; F Bellini; M Mannelli; N Misciglia; C Mavilia; U Vellei; D Villari; M Serio Journal: J Am Soc Nephrol Date: 1999-02 Impact factor: 10.121
Authors: S Fukuda; T Shirahama; Y Imazono; T Tsushima; H Ohmori; T Kayajima; S Take; K Nishiyama; S Yonezawa; S Akiba; S Akiyama; Y Ohi Journal: Cancer Date: 1999-03-15 Impact factor: 6.860
Authors: P Carmeliet; Y Dor; J M Herbert; D Fukumura; K Brusselmans; M Dewerchin; M Neeman; F Bono; R Abramovitch; P Maxwell; C J Koch; P Ratcliffe; L Moons; R K Jain; D Collen; E Keshert; E Keshet Journal: Nature Date: 1998-07-30 Impact factor: 49.962
Authors: N Burrows; J Resch; R L Cowen; R von Wasielewski; C Hoang-Vu; C M West; K J Williams; G Brabant Journal: Endocr Relat Cancer Date: 2010-01-29 Impact factor: 5.678
Authors: A M Jubb; H Turley; H C Moeller; G Steers; C Han; J-L Li; R Leek; E Y Tan; B Singh; N J Mortensen; I Noguera-Troise; F Pezzella; K C Gatter; G Thurston; S B Fox; A L Harris Journal: Br J Cancer Date: 2009-10-20 Impact factor: 7.640